Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endothelial dysfunction one-year after transplantation mainly depends on transplant-associated factors and only marginally on reduced renal function.

OBJETIVES Primary objective Estimate the contribution of renal dysfunction to endothelial dysfunction in two cohorts of patients, living kidney donors and their transplant recipients.

Secondary objectives

To evaluate in both cohorts of patients before and after nephrectomy/transplantation the evolution of the following parameters:

1. Renal function (iohexolGFR, proteinuria/microalbuminuria).
2. Blood pressure (24 h ambulatory blood pressure measurement)
3. Surrogate variables of subclinical atherosclerosis (carotid ultrasound, ankle-brachial index, pulse wave velocity).

DESIGN Non-interventional, prospective, multicenter, longitudinal study of two cohorts: living kidney donors and their transplant recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study

NCT02555566

Kidney Transplant Recipients

COMPLETED NA

The Study of Long-term Deterioration of Kidney Transplants.

NCT00217126

Kidney Transplant

COMPLETED

Long-term Cardiovascular Risk Following Successful Renal Transplantation

NCT01728012

Renal Transplant

COMPLETED

Different Vascular and Renal Parameters in Living Kidney Donors

NCT06056466

Renal Injury

COMPLETED

The Role of Biomarkers in the Early Detection of Acute Kidney Injury Induced by Liver Transplantation

NCT01333319

Acute Kidney Injury

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HYPOTHESIS

BACKGROUND: Chronic kidney disease (CKD) is associated with endothelial dysfunction, but the link between cardiovascular risk and CKD is difficult to establish because other conditions such as diabetes, hypertension and transplant-related factors are present in these patients. Living donors are healthy individuals that represent a near-ideal experimental model of CKD since they undergo a time-defined reduction of GFR after nephrectomy in the absence of other confounding factors present in patients with mild to moderate CKD.

HYPOTHESIS: Reduction of GFR after donation is associated with increased while renal transplantation is associated with reduced endothelial dysfunction markers.

AIM: To prospectively evaluate biomarkers of endothelial dysfunction and surrogate variables of subclinical atherosclerosis in a cohort of living kidney donors before and one year after donation and in their recipients before and one year after transplantation.

PATIENTS AND METHODS: In two cohorts of 60 living kidney donors (1 month before and 1 year after donation) and in their 60 renal transplant recipients (1 month before and 1 year after transplantation) the following variables will be recorded: iohexol glomerular filtration rate (GFR), proteinuria, microalbuminuria, insulinemia, oral glucose tolerance test, total and LDL/HDL cholesterol, number of carotid plaques and intima-media thickness, carotid-femoral pulse wave velocity, ankle-brachial index, 24-hours ambulatory monitoring of blood pressure. The following biomarkers of endothelial dysfunction and subclinical inflammation will be determined: SVCAM-1, PTX3, ICAM-1, von Willebrand factor, E-selectin, platelet/endothelial cell adhesion molecule (PECAM1), interleukin 6 (IL-6), soluble receptor of tumor necrosis factor (sTNFR1 and sTNFR2), high sensitive C reactive protein (hs-CRP) and soluble TNF-like weak inducer of apoptosis (sTWEAK).

EXPECTED RESULTS. In healthy subjects decrease of renal function after living donation will be associated with increased endothelial dysfunction markers. On the contrary, after transplantation a decrease of endothelial dysfunction markers will be observed. Despite at one year both cohorts of patients will have a similar GFR, the investigators expect that amelioration of endothelial dysfunction in transplants will be higher than worsening of endothelial dysfunction in their donors. Thus, the study of these two cohorts will allow estimating the contribution of renal dysfunction per se and transplant-associated comorbidities to endothelial dysfunction in chronic kidney disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorder Related to Renal Transplantation Chronic Kidney Disease Endothelial Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Endothelial dysfunction in Cohort 1

Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.

Endothelial dysfunction

Intervention Type OTHER

One month before surgery and one year after, the following procedures will be performed in donors and recipients:

1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.
2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.
3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor
4. Estimation of glomerular filtration rate by Iohexol method

Endothelial dysfunction in Cohort 2

Assessment of endothelial dysfunction in renal transplant recipients from cohort 1

Endothelial dysfunction

Intervention Type OTHER

One month before surgery and one year after, the following procedures will be performed in donors and recipients:

1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.
2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.
3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor
4. Estimation of glomerular filtration rate by Iohexol method

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endothelial dysfunction

One month before surgery and one year after, the following procedures will be performed in donors and recipients:

1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.
2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.
3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor
4. Estimation of glomerular filtration rate by Iohexol method

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No history of familiar nephropathies and/other diseases that may increase the risk for renal disease in the future.
* Donor age ≥ 18 years
* Isotopic GFR \> 80 ml/min/1.73m2
* Microalbuminuria\< 30 mg/g
* Normal urinary sediment
* Normal blood pressure defined as \<120/90 mmHg and without other risk factors for cardiovascular disease, and with good/normal kidney function or well-controlled hypertension with one anti-hypertensive drug,
* No previous history of diabetes including gestational diabetes and fasting glucose \< 126 mg/dl and 2h serum glucose after 75 g oral glucose tolerance test \< 200 mg/dl
* Signed informed consent

* Chronic kidney disease stage 5
* Negative complement dependent lymphocytotoxicity donor-recipient cross-match.
* Informed signed consent

Exclusion Criteria

* History of cancer except non-melanoma cutaneous neoplasia
* History of vasculitis (e.g. lupus), sarcoidosis, gastrointestinal inflammatory diseases, autoimmune-disease
* History of major cardiovascular events
* History of deep vein thrombosis or pulmonary embolism.
* Active infection including hepatitis B, C and HIV infections.
* Anatomic vascular variants precluding laparoscopic nephrectomy
* Renal stones except a solitary lithiasis\< 1.5 cm once metabolic disorders are ruled out
* Major psychiatric disorders
* Active alcohol, tobacco or drug abuse
* Obesity defined as body mass index \> 35 kg/m2.
* Pregnancy

* Glomerulonephritis with high recurrence rate after transplantation (focal segmental glomerulosclerosis and type II membranoproliferative glomerulonephritis)
* Severe aortoiliac atherosclerosis precluding transplantation
* Major psychiatric disorders
* Alcohol and drug abuse
* Active infection
* Patients requiring desensitization treatment before transplantation.
* Pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No